Elisabeth A. Pedersen

Dr. Elisabeth A. Pedersen

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
AHAllegra G. Hawkins
Allegra G. Hawkins
EPElisabeth A. Pedersen
Elisabeth A. Pedersen
STSydney Treichel
Sydney Treichel
KTKelsey Temprine
Kelsey Temprine
CSColin Sperring
Colin Sperring
ELElizabeth R Lawlor
Elizabeth R Lawlor
Wnt/β-catenin signaling is active in small subpopulations of Ewing sarcoma cells, and these cells display a more metastatic phenotype, in part due to antagonism of EWS-FLI1–dependent transcriptional activity. Importantly, these β-catenin–activated Ewing sarcoma cells also alter secretion of extracellular matrix (ECM) proteins. We thus hypothesized that, in addition to cell-autonomous mechanisms, Wnt/β-catenin–active tumor cells might contribute to disease progression by altering the tumor microenvironment (TME). Analysis of transcriptomic data from primary patient biopsies and from β-catenin–active versus –nonactive tumor cells identified angiogenic switch genes as being highly and reproducibly upregulated in the context of β-catenin activation. In addition, in silico and in vitro analyses, along with chorioallantoic membrane assays, demonstrated that β-catenin–activated Ewing cells secreted factors that promote angiogenesis. In particular, activation of canonical Wnt signaling leads Ewing sarcoma cells to upregulate expression and secretion of proangiogenic ECM proteins, collectively termed the angiomatrix. Significantly, our data show that induction of the angiomatrix by Wnt-responsive tumor cells is indirect and is mediated by TGF-β. Mechanistically, Wnt/β-catenin signaling antagonizes EWS-FLI1–dependent repression of TGF-β receptor type 2, thereby sensitizing tumor cells to TGF-β ligands. Together, these findings suggest that Wnt/β-catenin–active tumor cells can contribute to Ewing sarcoma progression by promoting angiogenesis in the local TME.

24 December 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
GOGrace A. Osborne
Grace A. Osborne
LZLin Zhang
Lin Zhang
FMFeiyang Ma
Feiyang Ma
MGMehrnaz Gharaee-Kermani
Mehrnaz Gharaee-Kermani
JTJessica L. Turnier
Jessica L. Turnier
MKMichelle Kahlenberg
Michelle Kahlenberg
Dermatomyositis is a rare yet devastating autoimmune disease characterized by inflammatory and vasculopathic changes in skin and muscle. Dermatomyositis and systemic lupus erythematosus (lupus) skin lesions have overlapping clinical and histopathological features but show disparate responses to available therapeutics, with dermatomyositis skin disease often relapsing and being recalcitrant. To investigate dermatomyositis immunopathogenesis, nonlesional skin, lesional skin, and circulating immune cells from patients with dermatomyositis were analyzed using single-cell RNA sequencing. Samples were analyzed in parallel with lesional and nonlesional lupus skin, healthy control skin, and peripheral blood from all three patient groups. We demonstrate a pervasive type I interferon signature in dermatomyositis stroma that persisted in culture and was distinguished from lupus by up-regulation of vascular endothelial growth factor and interleukin-18 signaling in dermatomyositis keratinocytes. Furthermore, endothelial cells in lesional dermatomyositis exhibited decreased proliferation, which was not observed in lupus skin. Using cell communication networks, we identified a population of dermatomyositis-specific monocytes interacting with nonproliferating endothelial cells. Coculture of monocytes from patients with dermatomyositis with endothelial cells resulted in increased endothelial cell apoptosis, which was inhibited by Janus kinase 1 (JAK1) blockade. JAK1 inhibition also resulted in reversal of dermatomyositis stromal and inflammatory signatures. Together, our data provide a comprehensive cross-disease characterization of lesional and nonlesional skin in dermatomyositis and implicate monocyte-mediated endothelial cell dysfunction in dermatomyositis vasculopathy. Moreover, these results suggest that JAK inhibition may offer a suitable therapeutic intervention for refractory skin disease.

13 November 2022 in JAAD Case Reports
Verified
Journal Article
Open access
KYKelly Z. Young
Kelly Z. Young
NBNaomi F. Briones
Naomi F. Briones
EPElisabeth A. Pedersen
Elisabeth A. Pedersen
DFDouglas Fullen
Douglas Fullen
FWFrank Wang
Frank Wang

10 December 2022 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
EPElisabeth A. Pedersen
Elisabeth A. Pedersen
PHPaul W. Harms
Paul W. Harms
LZLili Zhao
Lili Zhao
AAAleodor A. Andea
Aleodor A. Andea
DFDouglas R. Fullen
Douglas R. Fullen
ADAlison B. Durham
Alison B. Durham

10 August 2024 in JAAD Case Reports
Verified
Journal Article
Open access
DWDaniel Wenzel
Daniel Wenzel
ASAndrew M. Schuler
Andrew M. Schuler
DSDavid C. Smith
David C. Smith
JEJoseph R. Evans
Joseph R. Evans
KHKelly L. Harms
Kelly L. Harms
EPElisabeth A. Pedersen
Elisabeth A. Pedersen

16 December 2025 in JID Innovations
Verified
Journal Article
Open access
EPElisabeth A. Pedersen
Elisabeth A. Pedersen
MGMarina Grachtchouk
Marina Grachtchouk
PHPaul Harms
Paul Harms
AFAllison K.C. Furgal
Allison K.C. Furgal
DWDawn Wilbert
Dawn Wilbert
ADAndrzej A. Dlugosz
Andrzej A. Dlugosz
Basal cell carcinoma (BCC) is the most common skin malignancy, and the risk of developing BCC increases with age. BCC results from dysregulated Hedgehog signaling leading to activation of GLI transcription factors. In this study, we examined the impact of aging on BCC in cohorts of young (n = 37) versus aged (n = 97) mice using a transgenic mouse model in which GLI2A (GLI2 activator) was induced in mice at either the age of 7 weeks or 22–24 months, and BCC tumor development was monitored by weekly imaging. Young mice developed tumors slightly sooner and in greater numbers than aged mice but demonstrated similar growth rates once tumors appeared. However, BCC-associated increases in blood vessel diameter, tortuosity, and ulceration were impacted by age. BCCs in both young and aged mice underwent similarly rapid regression after GLI2A transgene inactivation. Taken together, our findings reveal that aging affects tumor-associated vasculature but not BCC formation or regression in our model. These results are in keeping with the notion that a major contributor to the increased incidence of BCCs in elderly patients is the accumulation of oncogenic driver mutations over time rather than intrinsic changes in aged skin that promote BCC tumorigenesis.